Julphar to commence insulin production at new facility
The factory that is worth Dh500m ($136.92m) is believed to have a capacity of producing 1,500kg and 50 million vials of the raw insulin every year. The main
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.